Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study.

Sánchez-Rovira P, Antón A, Barnadas A, Velasco A, Lomas M, Rodríguez-Pinilla M, Ramírez JL, Ramírez C, Ríos MJ, Castellá E, García-Andrade C, San Antonio B, Carrasco E, Palacios JL.

Clin Transl Oncol. 2012 Jun;14(6):430-6. doi: 10.1007/s12094-012-0820-4.

PMID:
22634531
[PubMed - indexed for MEDLINE]
2.

Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.

Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y.

J BUON. 2013 Jan-Mar;18(1):57-63.

PMID:
23613389
[PubMed - indexed for MEDLINE]
3.
4.

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).

Zambetti M, Mansutti M, Gomez P, Lluch A, Dittrich C, Zamagni C, Ciruelos E, Pavesi L, Semiglazov V, De Benedictis E, Gaion F, Bari M, Morandi P, Valagussa P, Luca G.

Breast Cancer Res Treat. 2012 Apr;132(3):843-51. doi: 10.1007/s10549-011-1660-6. Epub 2011 Jul 13.

PMID:
21750964
[PubMed - indexed for MEDLINE]
5.

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.

Breast Cancer Res. 2008;10(2):R30. doi: 10.1186/bcr1989. Epub 2008 Apr 1.

PMID:
18380893
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.

Lee J, Im YH, Lee SH, Cho EY, Choi YL, Ko YH, Kim JH, Nam SJ, Kim HJ, Ahn JS, Park YS, Lim HY, Han BK, Yang JH.

Cancer Chemother Pharmacol. 2008 Apr;61(4):569-77. Epub 2007 May 17.

PMID:
17508214
[PubMed - indexed for MEDLINE]
7.

Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.

Sarid D, Ron IG, Sperber F, Stadler Y, Kahan P, Kovner F, Ben-Yosef R, Marmor S, Grinberg Y, Maimon N, Weinstein J, Yaal-Hahoshen N.

Clin Drug Investig. 2006;26(12):691-701.

PMID:
17274676
[PubMed - indexed for MEDLINE]
8.

Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients.

Ezzat AA, Ibrahim EM, Ajarim DS, Rahal MM, Raja MA, Tulbah AM, Al-Malik OA, Al-Shabanah M, Sorbris R.

Br J Cancer. 2004 Mar 8;90(5):968-74.

PMID:
14997191
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.

Sánchez-Rovira P, Jaén A, González E, Porras I, Dueñas MR, Medina B, Mohedano N, Fernández M, Martos M, Lozano A.

Clin Breast Cancer. 2000 Oct;1(3):226-32.

PMID:
11899647
[PubMed - indexed for MEDLINE]
10.

Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients.

Sánchez-Muñoz A, Dueñas-García R, Jaén-Morago A, Carrasco E, Chacón I, García-Tapiador AM, Ortega-Granados AL, Martínez-Ortega E, Ribelles N, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Martínez J, Tortosa CR, Martín-Salvago MD, Sánchez-Rovira P.

Am J Clin Oncol. 2010 Oct;33(5):432-7. doi: 10.1097/COC.0b013e3181b4eff9.

PMID:
19952716
[PubMed - indexed for MEDLINE]
11.

Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.

Passardi A, Massa I, Zoli W, Gianni L, Milandri C, Zumaglini F, Nanni O, Maltoni R, Frassineti GL, Amadori D.

BMC Cancer. 2006 Mar 21;6:76.

PMID:
16551351
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.

Hamm JT, Wilson JW, Rastogi P, Lembersky BC, Tseng GC, Song YK, Kim W, Robidoux A, Raymond JM, Kardinal CG, Shalaby IA, Ansari R, Paik S, Geyer CE, Wolmark N; NSABP Foundation Research Group.

Clin Breast Cancer. 2008 Jun;8(3):257-63. doi: 10.3816/CBC.2008.n.029.

PMID:
18650156
[PubMed - indexed for MEDLINE]
13.

Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.

Yasojima H, Shimomura A, Naoi Y, Kishi K, Baba Y, Shimazu K, Nakayama T, Kim SJ, Tamaki Y, Noguchi S.

Eur J Cancer. 2011 Aug;47(12):1779-88. doi: 10.1016/j.ejca.2011.06.017. Epub 2011 Jul 7.

PMID:
21741827
[PubMed - indexed for MEDLINE]
14.

ER, PgR, HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.

Li XR, Liu M, Zhang YJ, Wang JD, Zheng YQ, Li J, Ma B, Song X.

Med Oncol. 2011 Dec;28 Suppl 1:S48-54. doi: 10.1007/s12032-010-9693-y. Epub 2010 Sep 25.

PMID:
20872186
[PubMed - indexed for MEDLINE]
15.

Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.

Gogas H, Pectasides D, Kostopoulos I, Lianos E, Skarlos D, Papaxoinis G, Bobos M, Kalofonos HP, Petraki K, Pavlakis K, Bafaloukos D, Fountzilas G.

Clin Breast Cancer. 2010 Jun;10(3):230-7. doi: 10.3816/CBC.2010.n.031.

PMID:
20497922
[PubMed - indexed for MEDLINE]
16.

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.

Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM.

Cancer. 2007 Jul 15;110(2):244-54.

PMID:
17538978
[PubMed - indexed for MEDLINE]
Free Article
17.

[Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].

Yin HF, Wang YH, Qin XQ, Zhang H, Li T, Ye JM, Liu YH.

Zhonghua Zhong Liu Za Zhi. 2009 Nov;31(11):858-62. Chinese.

PMID:
20137353
[PubMed - indexed for MEDLINE]
18.

Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months.

Huang O, Chen C, Wu J, Chen S, Chen X, Liu G, Hu Z, Lu J, Wu J, Shao Z, Shen Z, Shen K.

BMC Cancer. 2009 Oct 21;9:375. doi: 10.1186/1471-2407-9-375.

PMID:
19845944
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.

Rastogi P, Buyse ME, Swain SM, Jacobs SA, Robidoux A, Liepman MK, Pajon ER, Dy PA, Posada JG Jr, Melnik MK, Piette F, Geyer CE Jr, Mamounas EP, Wolmark N.

Clin Breast Cancer. 2011 Aug;11(4):228-34. doi: 10.1016/j.clbc.2011.04.001. Epub 2011 May 4.

PMID:
21684812
[PubMed - indexed for MEDLINE]
20.

Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.

Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N.

Breast Cancer. 2010 Oct;17(4):269-75. doi: 10.1007/s12282-009-0161-5.

PMID:
19730975
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk